Literature DB >> 16927402

Adaptive, group sequential and decision theoretic approaches to sample size determination.

Cyrus R Mehta1, Nitin R Patel.   

Abstract

This paper presents two adaptive methods for sample size re-estimation within a unified group sequential framework. The conceptual and practical distinction between these adaptive modifications and more traditional sample size changes due to revised estimates of nuisance parameters is highlighted. The motivation for the adaptive designs is discussed. Having established that adaptive sample size modifications can be made without inflating the type 1 error, the paper concludes with a novel decision theoretic approach for determining the magnitude of the sample size modification. Copyright 2006 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16927402     DOI: 10.1002/sim.2638

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

Review 1.  Integrating predictive biomarkers and classifiers into oncology clinical development programmes.

Authors:  Robert A Beckman; Jason Clark; Cong Chen
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

Review 2.  The future of drug development: advancing clinical trial design.

Authors:  John Orloff; Frank Douglas; Jose Pinheiro; Susan Levinson; Michael Branson; Pravin Chaturvedi; Ene Ette; Paul Gallo; Gigi Hirsch; Cyrus Mehta; Nitin Patel; Sameer Sabir; Stacy Springs; Donald Stanski; Matthias R Evers; Edd Fleming; Navjot Singh; Tony Tramontin; Howard Golub
Journal:  Nat Rev Drug Discov       Date:  2009-10-09       Impact factor: 84.694

3.  Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine-Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats.

Authors:  Bruno P Meloni; Diego Milani; Jane L Cross; Vince W Clark; Adam B Edwards; Ryan S Anderton; David J Blacker; Neville W Knuckey
Journal:  Neuromolecular Med       Date:  2017-05-18       Impact factor: 3.843

4.  Adaptive designs for comparative effectiveness research trials.

Authors:  John A Kairalla; Christopher S Coffey; Mitchell A Thomann; Ronald I Shorr; Keith E Muller
Journal:  Clin Res Regul Aff       Date:  2014-11-13

Review 5.  The future of clinical trials in urological oncology.

Authors:  Vikram M Narayan; Philipp Dahm
Journal:  Nat Rev Urol       Date:  2019-10-11       Impact factor: 14.432

Review 6.  Decision-theoretic designs for small trials and pilot studies: A review.

Authors:  Siew Wan Hee; Thomas Hamborg; Simon Day; Jason Madan; Frank Miller; Martin Posch; Sarah Zohar; Nigel Stallard
Journal:  Stat Methods Med Res       Date:  2015-06-05       Impact factor: 3.021

7.  Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.

Authors:  Michael Pearce; Siew Wan Hee; Jason Madan; Martin Posch; Simon Day; Frank Miller; Sarah Zohar; Nigel Stallard
Journal:  BMC Med Res Methodol       Date:  2018-02-08       Impact factor: 4.615

8.  Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.

Authors:  Andrew Satlin; Jinping Wang; Veronika Logovinsky; Scott Berry; Chad Swanson; Shobha Dhadda; Donald A Berry
Journal:  Alzheimers Dement (N Y)       Date:  2016-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.